Duality Biologics and BioNTech Highlight Interim Data from P-I/IIa Trial of BNT324/DB-1311 in Advanced Solid Tumors at ESMO Asia 2...
Shots: The P-I/IIa study assessed BNT324 (B7-H3 targeting ADC) in heavily pretreat...
Shots: The P-I/IIa study assessed BNT324 (B7-H3 targeting ADC) in heavily pretreat...
Shots: Daiichi Sankyo reported pooled analysis from P-II (
Shots: The P-II trial assessed VVN461 (1.0% & 0.5%) vs vehicle for post-catara...
Shots: Eli Lilly reported topline data from P-IIIb (
Shots: The P-Ib/IIa study assessed EVER001 (XNW1011) to treat patients (n=31) with...
Shots: InventisBio has reported the results from P-II study assessing the safety &...
Incisive News in 3 Shots.
Modal body text goes here.